Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087918 | 0.83 | ADORA3 (0.62) | ADORA3ADORA2AADORA1ADORA2BNUDT1 | |
| SCHEMBL16628741 | 0.83 | HTT (0.61) | ADORA3ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL3096053 | 0.81 | ADORA3 (0.59) | ADORA3ADORA2AADORA1ADORA2BHTT | |
| SCHEMBL3081056 | 0.81 | ADORA2A (0.70) | ADORA3ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL3087861 | 0.80 | ADORA3 (0.65) | ADORA3ADORA2AADORA1ADORA2BNUDT1 | |
| SCHEMBL3094118 | 0.80 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL3081770 | 0.80 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BHSP90AA1 | |
| SCHEMBL16628837 | 0.80 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL16628795 | 0.78 | ADORA3 (0.66) | ADORA3ADORA2AADORA1ADORA2BALDH1A1 | |
| SCHEMBL3076505 | 0.78 | ADORA2A (0.68) | ADORA3ADORA2AADORA1ADORA2BAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3301/4885ADORA2A 4016/4885ADORA1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.